The newly formed International Serious Adverse Events Consortium (SAEC) plans to launch 2 initial research programs designed to identify genetic markers that may help predict which individuals are at risk for serious drug-related adverse events.
The studies will address drug-related liver toxicity and the rare but serious drug-related skin condition Stevens-Johnson syndrome. Patients respond differently to medicines, and all medicines can have side effects in some individuals.
The SAEC's work is based on the hypothesis that these differences have a genetic basis, and its research studies will examine the impact genes can have on how individuals respond to drugs. The findings will be made available to the research community for further study. The groups' objectives are as follows:
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs